A Study To Evaluate The Clinical Outcome Of Chimeric Antigen Receptor T-cell Therapy
Overview
Tab Title Description
Study type
ObservationalDescribes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study IDs
Site IRB
- Rochester, Minnesota: 18-009141
Sponsor Protocol Number: 18-009141
About this study
CAR-T therapy is a new therapy that is a promising strategy to treat certain types of cancer. FDA has approved 5 CAR-T therapy to treat pediatric and young adult with B-cell acute lymphoblastic leukemia (B-ALL) and adults with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). There are more clinical trials underway to test this treatment modality in different setting in these cancers and to test CAR-T in other types of cancer. As we transition CART into real-world clinical practice, it is important to see if the clinical outcome such as clinical response and side effects reported in clinical trials are the same in real-world practice. If these clinical outcomes are different, it would be important to examine factors that could contribute to the difference in outcome so that we can improve the clinical outcome for this treatment in clinical practice. In addition, long term outcome data with this therapy is very limited, and it would be important to describe clinical course of patients who have receive this therapy.
Participation eligibility
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Adult patients (age >= 18 years old) who is deemed eligible to receive FDA approved cell therapy to treat their cancer.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
| Mayo Clinic Location |
Status |
|
Rochester, Minn.
Mayo Clinic principal investigator Yi Lin, M.D., Ph.D. |
Closed for enrollment |
|
More information
Publications
Publications are currently not available